{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:22:54Z","timestamp":1791235374744,"version":"4.1.0"},"reference-count":66,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T00:00:00Z","timestamp":1579046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Schizophrenia is a severe mental disorder characterized by a heterogeneous symptom profile which comprises a clinical platform for widespread use of polypharmacy even though antipsychotic monotherapy is the recommended treatment regimen. This narrative review provides a summary of the current gap between evidence and practice for use of antipsychotic combination therapy in patients with schizophrenia. Antipsychotic polypharmacy is frequently prescribed instead of following international consensus of clozapine monotherapy in treatment\u2010resistant patients. Antipsychotic\u2010benzodiazepine combination therapy clearly has a role in the treatment of acute agitation whereas there is no evidence to support an effect on core schizophrenia symptoms when chronically prescribed. Antidepressants are typically added to antipsychotic treatment in case of persistent negative symptoms. Available evidence suggests that antidepressants may improve negative symptom control in schizophrenia. Combining an antipsychotic with an antiepileptic is not supported by any firm evidence, but individual mood stabilizers have come out positively in single trials. Generally, the evidence base for polypharmacy in schizophrenia maintenance treatment is sparse but may be warranted in certain clinical situations. Therapeutic benefits and side effects should be carefully monitored and considered to ensure a beneficial risk\u2010benefit ratio if prescribing polypharmacy for specific clinical indications.<\/jats:p>","DOI":"10.1111\/bcpt.13384","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T07:40:48Z","timestamp":1578382848000},"page":"183-192","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Polypharmacy in schizophrenia"],"prefix":"10.1111","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1662-2720","authenticated-orcid":false,"given":"Lone","family":"Baandrup","sequence":"first","affiliation":[{"name":"Centre for Neuropsychiatric Schizophrenia Research (CNSR) Mental Health Centre Glostrup Glostrup Denmark"},{"name":"Mental Health Centre Copenhagen Hellerup Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,1,15]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.67"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125311430110"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114563634"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31135-3"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.apha.2017.09.009"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.111.105833"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800330013001"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.4.600"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/eip.12683"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12193"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(18)30090-7"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2018.17091001"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2009.04.003"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/15622975.2012.696143"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1115"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2012.03.018"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.54.1.55"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2016.04.010"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3281084ea8"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.4.700"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2006.02.023"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04818yel"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2011.1532"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12906"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201800504"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S199748"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2009.01367.x"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318036bfbb"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbn018"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbn030"},{"key":"e_1_2_9_32_1","first-page":"CD006324","article-title":"Clozapine combined with different antipsychotic drugs for treatment\u2010resistant schizophrenia","volume":"3","author":"Barber S","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20387"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2011.08.005"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbr004"},{"key":"e_1_2_9_36_1","first-page":"CD009005","article-title":"Antipsychotic combinations for schizophrenia","volume":"6","author":"Ortiz\u2010Orendain J","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.0624"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2018.4320"},{"key":"e_1_2_9_39_1","volume-title":"The Maudsley Prescribing Guidelines in Psychiatry","author":"Taylor D","year":"2018"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2019.02.005"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10060908"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2015.05.038"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09321"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2019.05.030"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125314558054"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4767-6"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-011-0308-0"},{"key":"e_1_2_9_48_1","first-page":"67","article-title":"Antipsychotic medication use patterns and assocaited costs of care for individuals with schizophrenia","volume":"62","author":"Loosbrock DL","year":"2003","journal-title":"J Ment Health Policy Econ."},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2015.01.018"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1611832"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.15050618"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1014796"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0535-3"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.yco.0000165594.60434.84"},{"key":"e_1_2_9_55_1","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3109\/15622975.2015.1048725","article-title":"Prolonged\u2010release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia or bipolar disorder: a randomised, placebo\u2010controlled, blinded trial","volume":"17","author":"Baandrup L","year":"2016","journal-title":"World J Biol Psychiatry."},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2016.04.031"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-016-1062-8"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2017.03.009"},{"key":"e_1_2_9_59_1","first-page":"CD011481","article-title":"Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users","volume":"3","author":"Baandrup L","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbl057"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(18)30050-6"},{"key":"e_1_2_9_62_1","unstructured":"GartlehnerG HansenR MorganL et al.Second\u2010generation antidepressants in the pharmacologic treatment of adult depression: an update of the 2007 comparative effectiveness review. AHRQ Publ No 12\u2010EHC012\u2010EF 1\u2013954.Rockville (MD):Agency for Healthcare Research and Quality (US)."},{"key":"e_1_2_9_63_1","first-page":"CD003499","article-title":"Antiepileptics for aggression and associated impulsivity","author":"Huband N","year":"2010","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2009.01.002"},{"issue":"10","key":"e_1_2_9_65_1","first-page":"CD003834","article-title":"Lithium for schizophrenia","author":"Leucht S","year":"2015","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2018.4489"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03688.x"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcpt.13384","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.13384","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcpt.13384","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.13384","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T05:18:38Z","timestamp":1694063918000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.13384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,15]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1111\/bcpt.13384"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.13384","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,15]]},"assertion":[{"value":"2019-10-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}